AR099376A1 - Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos - Google Patents

Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos

Info

Publication number
AR099376A1
AR099376A1 ARP140104825A ARP140104825A AR099376A1 AR 099376 A1 AR099376 A1 AR 099376A1 AR P140104825 A ARP140104825 A AR P140104825A AR P140104825 A ARP140104825 A AR P140104825A AR 099376 A1 AR099376 A1 AR 099376A1
Authority
AR
Argentina
Prior art keywords
substituted
compositions
compounds
diaminopirimidil
those
Prior art date
Application number
ARP140104825A
Other languages
English (en)
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of AR099376A1 publication Critical patent/AR099376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

En la presente se proporcionan compuestos de diaminopirimidilo, composiciones que comprenden una cantidad eficaz de un compuesto de diaminopirimidilo, y métodos para tratar o prevenir trastornos mediados por la PKC-q o una condición que se puede tratar o prevenible mediante la inhibición de una quinasa, por ejemplo, PKC-q. Reivindicación 1: Un compuesto de formula (1) o una de sus sales, tautómeros, isotopólogos o estereoisómeros farmacéuticamente aceptables, donde: X es CN o CF₃; L es (alquilo C₁₋₄); R¹ es heteroarilo sustituido o no sustituido; y R² es cicloalquilo sustituido o no sustituido.
ARP140104825A 2013-12-20 2014-12-19 Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos AR099376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361919216P 2013-12-20 2013-12-20

Publications (1)

Publication Number Publication Date
AR099376A1 true AR099376A1 (es) 2016-07-20

Family

ID=53399293

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104825A AR099376A1 (es) 2013-12-20 2014-12-19 Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos

Country Status (16)

Country Link
US (3) US9556126B2 (es)
EP (2) EP3736268A1 (es)
JP (1) JP6483707B2 (es)
KR (1) KR20160095159A (es)
CN (1) CN106170290A (es)
AR (1) AR099376A1 (es)
AU (1) AU2014369031A1 (es)
BR (1) BR112016014412A2 (es)
CA (1) CA2934061A1 (es)
ES (1) ES2812605T3 (es)
IL (1) IL246252A0 (es)
MX (1) MX2016007898A (es)
RU (1) RU2016129380A (es)
SG (1) SG11201604821YA (es)
TW (1) TW201609671A (es)
WO (1) WO2015095679A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI681952B (zh) 2011-04-22 2020-01-11 美商標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
WO2014149819A1 (en) 2013-03-14 2014-09-25 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
WO2015089170A1 (en) 2013-12-12 2015-06-18 Kalyra Pharmaceuticals, Inc. Bicyclic alkyl compounds and synthesis
EP3736268A1 (en) * 2013-12-20 2020-11-11 Signal Pharmaceuticals, LLC Process for the preparation of substituted diaminopyrimidyl compounds
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
JP6741343B2 (ja) 2014-03-07 2020-08-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー プロペラン誘導体および合成
CA2961605C (en) 2014-09-17 2023-01-10 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
US10697760B2 (en) 2015-04-15 2020-06-30 General Electric Company Data acquisition devices, systems and method for analyzing strain sensors and monitoring component strain
CA2993173C (en) 2015-07-24 2023-10-03 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
US20190060257A1 (en) * 2016-03-16 2019-02-28 Zeno Royalties & Milestones, LLC Analgesic compounds
CN105906569B (zh) * 2016-05-24 2018-04-24 杰达维（上海）医药科技发展有限公司 一种嘧啶衍生物的制备方法
CA3060416A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
CA3063729A1 (en) 2017-05-15 2018-11-22 Recurium Ip Holdings, Llc Analgesic compounds
JP2021500327A (ja) * 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 免疫療法にｅｈｍｔ２阻害剤を使用する方法
CN107759477A (zh) * 2017-11-20 2018-03-06 阿里化学(常州)有限公司 一种对硝基苯乙胺盐酸盐的生产制备方法
CN108395408B (zh) * 2018-03-23 2021-03-09 杰达维（上海）医药科技发展有限公司 一种药物中间体及其制备方法
WO2020210521A2 (en) 2019-04-12 2020-10-15 The Regents Of The University Of California Compositions and methods for increasing muscle mass and oxidative metabolism
CN112574123A (zh) * 2019-09-30 2021-03-30 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途
CA3166936A1 (en) 2020-02-04 2021-08-12 Abdelmalik Slassi Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
KR20230130664A (ko) * 2021-01-08 2023-09-12 캄테크, 인크. 보호 알킬 트립타민 및 이의 치료적 용도
KR20240024063A (ko) 2021-05-06 2024-02-23 엑스사이언티아 에이아이 리미티드 Pkc-세타 조정제
CA3213703A1 (en) 2021-05-06 2022-11-10 Peter Ray Pkc-theta modulators

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU73300A (sh) 1998-05-26 2003-08-29 Warner-Lambert Company Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije
AU5108000A (en) 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
CA2451128A1 (en) 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
JPWO2003082855A1 (ja) 2002-03-28 2005-08-04 協和醗酵工業株式会社 抗炎症剤
DE602004021558D1 (de) * 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
CA2514612A1 (en) 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
WO2006014482A1 (en) 2004-07-08 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
EP1794134A1 (de) 2004-09-29 2007-06-13 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
ES2324837T3 (es) 2005-03-28 2009-08-17 Boehringer Ingelheim International Gmbh Derivados de piridina utiles como inhibidores de la pkc-theta.
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
JP2009521488A (ja) 2005-12-21 2009-06-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｋｃ−シータのインヒビターとして有益なピリミジン誘導体
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
PE20080068A1 (es) * 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
CA2704266A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
WO2009071535A1 (en) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
JP5302389B2 (ja) 2008-04-29 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー Ｊｎｋのピリミジニルピリドンインヒビター
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010024430A1 (ja) * 2008-09-01 2010-03-04 アステラス製薬株式会社 2,4-ジアミノピリミジン化合物
JP2012501981A (ja) 2008-09-03 2012-01-26 バイエル・クロップサイエンス・アーゲー 殺菌剤としてのヘテロ環置換アニリノピリミジン類
CN102203086A (zh) 2008-09-03 2011-09-28 拜尔农作物科学股份公司 作为杀真菌剂的噻吩基氨基嘧啶类化合物
WO2010025831A1 (de) 2008-09-03 2010-03-11 Bayer Cropscience Ag Heterozyklisch substituierte anilinopyrimidine als fungizide
EP2331512A1 (de) * 2008-09-03 2011-06-15 Bayer CropScience AG Alkoxy- und alkylthio-substituierte anilinopyrimidine
US8377924B2 (en) 2009-01-21 2013-02-19 Rigel Pharmaceuticals Inc. Protein kinase C inhibitors and uses thereof
JP2012148977A (ja) 2009-05-20 2012-08-09 Astellas Pharma Inc アミノシクロヘキシルアルキル基を有する２，４−ジアミノピリミジン化合物
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP2011173853A (ja) 2010-02-26 2011-09-08 Astellas Pharma Inc 置換アミノアダマンチルアルキル基を有する２，４−ジアミノピリミジン化合物
JP2011173854A (ja) 2010-02-26 2011-09-08 Astellas Pharma Inc ビシクロ環置換アルキル基を有する２，４−ジアミノピリミジン化合物
HUE046617T2 (hu) 2010-11-10 2020-03-30 Genentech Inc Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
RU2013132683A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
TWI681952B (zh) 2011-04-22 2020-01-11 美商標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
GB201108225D0 (en) * 2011-05-17 2011-06-29 Amakem Nv Novel KBC inhibitors
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2856306A1 (en) 2011-11-23 2013-05-30 Portola Pharmaceuticals, Inc. Selective kinase inhibitors
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
AU2012357038B2 (en) * 2011-12-23 2016-05-12 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
WO2013164323A1 (en) 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
MX363118B (es) 2012-05-03 2019-03-11 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
WO2014044025A1 (zh) 2012-09-20 2014-03-27 山东亨利医药科技有限责任公司 嘧啶胺衍生物及其制备方法和应用
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
EP3736268A1 (en) * 2013-12-20 2020-11-11 Signal Pharmaceuticals, LLC Process for the preparation of substituted diaminopyrimidyl compounds

Also Published As

Publication number Publication date
WO2015095679A1 (en) 2015-06-25
CA2934061A1 (en) 2015-06-25
CN106170290A (zh) 2016-11-30
US9156798B2 (en) 2015-10-13
IL246252A0 (en) 2016-07-31
KR20160095159A (ko) 2016-08-10
US20150175557A1 (en) 2015-06-25
US20160354374A1 (en) 2016-12-08
SG11201604821YA (en) 2016-07-28
JP6483707B2 (ja) 2019-03-13
US9556126B2 (en) 2017-01-31
AU2014369031A1 (en) 2016-07-07
EP3082819B1 (en) 2020-06-17
EP3082819A1 (en) 2016-10-26
BR112016014412A2 (pt) 2017-08-08
TW201609671A (zh) 2016-03-16
US9783505B2 (en) 2017-10-10
EP3082819A4 (en) 2017-08-23
ES2812605T3 (es) 2021-03-17
JP2017500325A (ja) 2017-01-05
RU2016129380A (ru) 2018-01-25
US20150246890A1 (en) 2015-09-03
MX2016007898A (es) 2016-10-07
EP3736268A1 (en) 2020-11-11

Similar Documents

Publication Publication Date Title
AR099376A1 (es) Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201591913A1 (ru) Ингибиторы протеинкиназы
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
PH12015500689A1 (en) Azaquinazoline inhibitors of atypical protein kinase c
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
AR103680A1 (es) Inhibidores selectivos de bace1
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
DOP2016000120A (es) Nuevos inhibidores de dgat2
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
EA201792288A1 (ru) Способы лечения рака
EA201592096A1 (ru) Ингибиторы никотинамид фосфорибозилтрансферазы, композиции, продукты и их применение

Legal Events

Date Code Title Description
FB Suspension of granting procedure